Toggle light / dark theme

Year 2015 face_with_colon_three


The genetically modified super-smart mice also proved to suffer less from anxiety, the scientists found.

For all that science has decoded the human genome, we don’t actually know what most of our DNA does, or even what a great many of our genes do. One way to elucidate what a gene does is to change it (mutate it) and see what happens.

This team from Britain and Canada found that mutating a single gene to block the phosphodiesterase-4B (PDE4B) enzyme, which is found in many organs including the brain, made mice cleverer and at the same time less fearful.

(https://isbscience.org/bio/leroy-hood/) is Co-Founder, Chief Strategy Officer and Professor, at the Institute of Systems Biology (ISB) in Seattle, as well as CEO of Phenome Health (https://phenomehealth.org/), a nonprofit organization dedicated to delivering value through health innovation focused on his P4 model of health (Predictive, Preventive, Personalized and Participatory) where a patient’s unique individuality is acknowledged, respected, and leveraged for the benefit of everyone.

Dr. Hood, who is a world-renowned scientist and recipient of the National Medal of Science in 2011, co-founded the Institute for Systems Biology (ISB) in 2000 and served as its first President from 2000–2017. In 2016, ISB affiliated with Providence St. Joseph Health (PSJH) and Dr. Hood became PSJH’s Senior Vice President and Chief Science Officer.

Dr. Hood is a member of the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Medicine. Of the more than 6,000 scientists worldwide who belong to one or more of these academies, Dr. Hood is one of only 20 people elected to all three.

Dr. Hood received his MD from Johns Hopkins University School of Medicine and his PhD in biochemistry from Caltech.

Imagine using your cellphone to control the activity of your own cells to treat injuries and disease. It sounds like something from the imagination of an overly optimistic science fiction writer. But this may one day be a possibility through the emerging field of quantum biology.

Over the past few decades, scientists have made incredible progress in understanding and manipulating at increasingly small scales, from protein folding to genetic engineering. And yet, the extent to which influence living systems remains barely understood.

Quantum effects are phenomena that occur between atoms and molecules that can’t be explained by . It has been known for more than a century that the rules of classical mechanics, like Newton’s laws of motion, break down at atomic scales. Instead, behave according to a different set of laws known as quantum mechanics.

The adoption of AI in clinical settings has increased exponentially over the past decade, but AI models still haven’t achieved the level of ubiquity that they could within the sector.

A few years ago, a group of Mayo Clinic researchers recognized this major problem. The health system was producing a huge amount of research on AI in clinical contexts, but it was still having a hard time actually deploying those AI models at scale.

That realization led to the creation of Lucem Health, a platform for clinical AI solution deployment. The North Carolina-based startup, which launched in 2021, closed a $7.7 million Series A funding round last week.

As sponges and ctenophores are such disparate animals13, the nature of the first diverging animal lineage has implications for the evolution of fundamental animal characteristics. Adult sponges are generally sessile filter-feeding organisms with body plans organized into reticulated water-filtration channels, structures built out of silica or calcium carbonate, and specialized cell types and tissues used for feeding, reproduction and self-defence, but they lack neuronal and muscle cells15. By contrast, ctenophores are gelatinous marine predators that move using eight longitudinal ‘comb rows’ of ciliary bundles16,17; they are superficially similar but unrelated to cnidarian medusae13,18 and possess multiple nerve nets19. Thus, whereas the sponge-sister scenario suggests a single origin of neurons on the ctenophore–parahoxozoan stem, the ctenophore-sister scenario implies either that either ancestral metazoan neurons were lost in the sponge lineage, or that there was convergent evolution of neurons in the ctenophore and parahoxozoan lineages3,6. Similar considerations apply to other metazoan cell types18, gene regulatory networks, animal development13,18 and other uniquely metazoan features.

Despite its importance for understanding animal evolution, the relative branching order of sponges, ctenophores and other animals has proven to be difficult to resolve2. The fossil record is largely silent on this issue as verified Precambrian sponge fossils are extremely rare20 and putative fossils of the soft-bodied ctenophores are difficult to interpret21. Morphological characters of living groups (for example, choanocytes of sponges) are not sufficient to resolve the question because true homology is difficult to assign, and such characters are easily lost or can arise convergently13,22. The ctenophore-sister hypothesis is supported by a pair of gene duplications shared by sponges, bilaterians, placozoans and cnidarians but not ctenophores23. Although sophisticated methods for sequence-based phylogenomics have been developed and applied to increasingly large molecular datasets, there is still considerable debate about the relative position of sponges and ctenophores as results are sensitive to how sequence evolution is modelled11, which taxa or sites are included24,25, and the effects of long-branch artifacts and nucleotide compositional variation26. New approaches are needed.

We reasoned that patterns of synteny, classically defined as chromosomal gene linkage without regard to gene order27, could provide a powerful tool for resolving the ctenophore-sister versus sponge-sister debate. Chromosomal patterns of gene linkage evolve slowly in many lineages12,28,29,30, probably because it is improbable for interchromosomal translocations to be fixed in populations with large effective population sizes28,31,32. Notably, some changes in synteny are effectively irreversible. For example, when two distinct ancestral synteny groups are combined onto a single chromosome by translocation, and subsequent intrachromosomal rearrangements mix these two groups of genes, it is very unlikely that the ancestral separated pattern will be restored by further rearrangement and fission, in the same sense that spontaneous reduction in entropy is improbable12. Such rare and irreversible changes are particularly useful for resolving challenging phylogenetic questions as they give rise to shared derived features that unambiguously unite all descendant lineages33,34,35. Deeply conserved syntenies observed between animals and their closest unicellular relatives12 suggest that outgroup comparisons could be used to infer ancestral metazoan states and polarize changes within animals to address the sponge-sister versus ctenophore-sister debate. Yet, chromosome-scale genome sequences of the unicellular or colonial eukaryotic outgroups closest to animals (choanoflagellates, filastereans and ichthyosporeans) have not been reported.

😗 year 2017.


Certain treatments for patients suffering from chronic diseases, such as inflammatory bowel diseases, require multiple intravenous or subcutaneous injections of specific drugs. Because of the pain and anxiety associated with needles, some patients stop adhering to these treatments.

MIT spinout Portal Instruments has now landed a commercialization deal for a smart, needle-free injection device that could reduce the pain and anxiety associated with needle injections, shorten administration time, and improve patient adherence.

Based on years of MIT research, the startup developed a jet-injection device that delivers a rapid, high-pressure stream of medicine, as thin as a strand of hair, through the skin in adjustable dosages, causing little to no pain. A connected app tracks each dose and the medicine’s effects, and uploads that information to the cloud, for patients and doctors. The device would be sold as a drug-device combination product to medical professionals and provided to patients with a prescription.